Next Article in Journal
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Previous Article in Journal
Statins and Cancer: A Complex Relationship Worth Exploring
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 16
Issue 11
10.3390/ph16111571
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Pharmaceuticals 2023, 16(8), 1164.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Joseph et al. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. Pharmaceuticals 2023, 16, 1164

by
Boney Joseph
1,2,†,
Nicolas A. Nunez
1,†,
Simon Kung
1,
Jennifer L. Vande Voort
1,
Vanessa K. Pazdernik
3,
Kathryn M. Schak
1,
Stacey M. Boehm
1,
Brooke Carpenter
1,
Emily K. Johnson
1,
Grigoriy Malyshev
1,
Nathan Smits
1,
Daniel O. Adewunmi
1,
Sarah K. Brown
1 and
Balwinder Singh
1,*,†
1
Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN 55905, USA
2
Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
3
Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Pharmaceuticals 2023, 16(11), 1571; https://doi.org/10.3390/ph16111571
Submission received: 19 October 2023 / Accepted: 26 October 2023 / Published: 7 November 2023
Browse Figure
Versions Notes

Error in Figure

In the original publication [1], there were mistakes in the Figure 2B. The correct Figure 2B appear below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Joseph, B.; Nunez, N.A.; Kung, S.; Vande Voort, J.L.; Pazdernik, V.K.; Schak, K.M.; Boehm, S.M.; Carpenter, B.; Johnson, E.K.; Malyshev, G.; et al. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. Pharmaceuticals 2023, 16, 1164. [Google Scholar] [CrossRef] [PubMed]
Pharmaceuticals 16 01571 g002
Figure 2. (A) Mean percent change in QIDS-SR 16 scores from baseline after each treatment and (B) mean CADSS score during treatment based on lamotrigine usage (N = 48). Abbreviations—CADSS: Clinician-Administered Dissociative Status Scale; QIDS-SR: 16-item Quick Inventory of Depressive Symptomatology self-report.
Figure 2. (A) Mean percent change in QIDS-SR 16 scores from baseline after each treatment and (B) mean CADSS score during treatment based on lamotrigine usage (N = 48). Abbreviations—CADSS: Clinician-Administered Dissociative Status Scale; QIDS-SR: 16-item Quick Inventory of Depressive Symptomatology self-report.
Pharmaceuticals 16 01571 g002
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Joseph, B.; Nunez, N.A.; Kung, S.; Vande Voort, J.L.; Pazdernik, V.K.; Schak, K.M.; Boehm, S.M.; Carpenter, B.; Johnson, E.K.; Malyshev, G.; et al. Correction: Joseph et al. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. Pharmaceuticals 2023, 16, 1164. Pharmaceuticals 2023, 16, 1571. https://doi.org/10.3390/ph16111571

AMA Style

Joseph B, Nunez NA, Kung S, Vande Voort JL, Pazdernik VK, Schak KM, Boehm SM, Carpenter B, Johnson EK, Malyshev G, et al. Correction: Joseph et al. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. Pharmaceuticals 2023, 16, 1164. Pharmaceuticals. 2023; 16(11):1571. https://doi.org/10.3390/ph16111571

Chicago/Turabian Style

Joseph, Boney, Nicolas A. Nunez, Simon Kung, Jennifer L. Vande Voort, Vanessa K. Pazdernik, Kathryn M. Schak, Stacey M. Boehm, Brooke Carpenter, Emily K. Johnson, Grigoriy Malyshev, and et al. 2023. "Correction: Joseph et al. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. Pharmaceuticals 2023, 16, 1164" Pharmaceuticals 16, no. 11: 1571. https://doi.org/10.3390/ph16111571

APA Style

Joseph, B., Nunez, N. A., Kung, S., Vande Voort, J. L., Pazdernik, V. K., Schak, K. M., Boehm, S. M., Carpenter, B., Johnson, E. K., Malyshev, G., Smits, N., Adewunmi, D. O., Brown, S. K., & Singh, B. (2023). Correction: Joseph et al. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. Pharmaceuticals 2023, 16, 1164. Pharmaceuticals, 16(11), 1571. https://doi.org/10.3390/ph16111571

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop